/PRNewswire/ Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today.
Calyxt (CLXT) to Merge with Cibus streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Treatments for blood cancer and rare diseases are the target markets, but investors are well aware of the challenges that await after approval is received.
Children with antibody-associated vasculitis, for instance, have a higher likelihood of upper airway disease and potentially severe lower airway disease.